Mitochondrial-targeted drug and DNA delivery

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 20, Issue 1, 2003, Pages 1-62

  Weissig, Volkmar ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; Delocalized cations; Drug targeting; Mitochondria; Mitochondrial delivery systems; Mitochondrial gene therapy

Indexed keywords

ACETOGENIN; ALPHA TOCOPHEROL; ANTHELMINTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CISPLATIN; CYANINE DYE; CYCLOSPORIN A; DEQUALINIUM; DOXORUBICIN; DRUG CARRIER; ETHIDIUM BROMIDE; FULLERENE DERIVATIVE; LIPOSOME; METHYLTRIPHENYLPHOSPHONIUM; MITOCHONDRIAL DNA; NEUROLEPTIC AGENT; PACLITAXEL; PEPTIDE NUCLEIC ACID; PLASTICIZER; RHODAMINE 123; ROLLINIASTATIN 1; ROTENONE; TERT BUTYL HYDROPEROXIDE; TRIPHENYLPHOSPHINE; UBIQUINONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; DRUG ACTIVITY; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; HUMAN; MEDICAL RESEARCH; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; PHOTODYNAMIC THERAPY; REVIEW;

APOPTOSIS; CARRIER PROTEINS; DNA; DNA, MITOCHONDRIAL; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; LIPOSOMES; MEMBRANE POTENTIALS; MITOCHONDRIA; PEPTIDE NUCLEIC ACIDS;

EID: 0042711191     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i1.10     Document Type: Review

References (296)

1. Singh KK. Mitochondrial me and the Mitochondrion journal. Mitochondrion 2000; 1(1):1-2.
2. Voet D, Voet JG, Pratt CW. Fundamentals of Biochemistry. New York: Wiley, 1999.
3. Modica-Napolitano JS, Singh KK. Mitochondria as targets for detection and treatment of cancer. Exp Rev Molec Med 2002; 11 April:1-19.
4. Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemiosmotic type of mechanism. Nature 1961; 191:144-8.
5. Nass S, Nass MMK. Intramitochondrial fibers with DNA characteristics. J Cell Biol 1963; 19:613-29.
6. Attardi G. In: DiMauro S, Wallace DC, editors. Mitochondrial DNA in Human Pathology. New York: Raven, 1993.
7. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, et al. Sequence and organization of the human mitochondrial genome. Nature 1981; 290(5806):457-65.
8. Chomyn A, Cleeter MW, Ragan CI, Riley M, Doolittle RF, Attardi G. URF6, last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit. Science 1986; 234(4776):614-8.
9. Chomyn A, Mariottini P, Cleeter MW, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G. Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. Nature 1985; 314(6012):592-7.
10. Brown GC, Nicholls DG, Cooper CE, editors. Mitochondria and Cell Death. Princeton, NJ: Princeton University Press, 1999; vii-viii.
11. Kroemer G. Mitochondrial control of apoptosis: an overview. In: Brown GC, Nicholls DG, Cooper CE, editors. Mitochondria and Cell Death. Princeton, NJ: Princeton University Press, 1999.
12. Murphy MP, Smith RA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 2000; 41(2):235-50.
13. Larson N-G, Luft R. Revolution in mitochondrial medicine. FEBS Lett 1999; 455:199-202.
14. Weissig V, Torchilin VP, editors. Drug and DNA delivery to mitochondria. Adv Drug Deliv Rev 2001; 49:1-215.
15. Szewczyk A, Wojtczak L. Mitochondria as a pharmacological target. Pharmacol Rev 2002; 54(1):101-27.
16. Manella CA. Our changing views of mitochondria. J Bioenerg Biomembr 2000; 32:1-4.
17. Perkins GA, Frey TG. Recent structural insight into mitochondria gained by microscopy. Micron 2000; 31:97-111.
18. Scheffler IE. Mitochondria make a come back. Adv Drug Deliv Rev 2001; 49(1-2):3-26.
19. Wallace KB, Starkov AA. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol 2000; 40:353-88.
20. Rowe TC, Weissig V, Lawrence JW. Mitochondrial DNA metabolism targeting drugs. Adv Drug Deliv Rev 2001; 49(1-2):175-87.
21. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ 2nd, Nikoskelainen EK. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988; 242(4884):1427-30.
22. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988; 331(6158):717-9.
23. Wallace DC. Mitochondrial diseases in man and mouse. Science 1999; 283(5407):1482-8.
24. Wallace DC. Mitochondrial defects in neurodegenerative disease. Ment Retard Dev Disabil Res Rev 2001; 7(3):158-66.
25. Wallace DC. A mitochondrial paradigm for degenerative diseases and aging. Novartis Found Symp 2001; 235:247-263; discussion 263-6.
26. Pulkes T, Hanna MG. Human mitochondrial DNA diseases. Adv Drug Deliv Rev 2001; 49(1-2):27-43.
27. DiMauro S, Schon EA. Mitochondrial DNA mutations in human disease. Am J Med Genet 2001; 106(1):18-26.
28. DiMauro S, Hirano M, Schon EA. Mitochondrial encephalomyopathies: therapeutic approaches. Neurol Sci 2000; 21(5 Suppl):S901-908.
29. Collombet JM, Coutelle C. Towards gene therapy of mitochondrial disorders. Mol Med Today 1998; 4(1):31-8.
30. Manfredi G, Beal MF. The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathol 2000; 10(3):462-72.
31. Weissig V, Torchilin VP. Towards mitochondrial gene therapy: DQAsomes as a strategy. J Drug Target 2001; 9(1):1-13.
32. Manfredi G, Fu J, Ojaimi J, Sadlock JE, Kwong JQ, Guy J, Schon EA. Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA - encoded gene, to the nucleus. Nat Genet 2002; 30(4):394-9.
33. Guy J, Qi X, Pallotti F, Schon EA, Manfredi G, Carelli V, Martinuzzi A, Hauswirth WW, Lewin AS. Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy. Ann Neurol 2002; 52(5):534-42.
34. Weissig V, Torchilin VP. Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems. Adv Drug Deliv Rev 2001; 49(1-2):127-49.
35. Kolesnikova OA, Entelis NS, Mireau H, Fox TD, Martin RP, Tarassov IA. Suppression of mutations in mitochondrial DNA by tRNAs imported from the cytoplasm. Science 2000; 289(5486):1931-3.
36. Entelis NS, Kolesnikova OA, Martin RP, Tarassov IA. RNA delivery into mitochondria. Adv Drug Deliv Rev 2001; 49(1-2):199-215.
37. Entelis NS, Kolesnikova OA, Dogan S, Martin RP, Tarassov IA. 5 S rRNA and tRNA import into human mitochondria. Comparison of in vitro requirements. J Biol Chem 2001; 276(49):45642-53.
38. de Grey AD. Mitochondrial gene therapy: an arena for the biomedical use of inteins. Trends Biotechnol 2000; 18(9):394-9.
39. Jacobs HT. Structural similarities between a mitochondrially encoded polypeptide and a family of prokaryotic respiratory toxins involved in plasmid maintenance suggest a novel mechanism for the evolutionary maintenance of mitochondrial DNA. J Mol Evol 1991; 32(4):333-9.
40. Geromel V, Cao A, Briane D, Vassy J, Rotig A, Rustin P, Coudert R, Rigaut JP, Munnich A, Taillandier E. Mitochondria transfection by oligonucleotides containing a signal peptide and vectorized by cationic liposomes. Antisense Nucleic Acid Drug Dev 2001; 11(3):175-80.
41. Chinnery PF, Taylor RW, Diekert K, Lill R, Turnbull DM, Lightowlers RN. Peptide nucleic acid delivery to human mitochondria. Gene Ther 1999; 6(12):1919-28.
42. D'Souza GG, Cheng SM, Torchilin VP, Weissig V. Towards mitochondrial gene therapy: DQAsomes deliver DNA to mitochondria in living mammalian cells. Proceedings of the 30th International Symposium on Controlled Release of Bioactive Materials. Glasgow, 2003. (In press.)
43. D'Souza GG, Rammohan R, Cheng SM,Torchilin VP, Weissig V. DQAsome-mediated plasmid DNA delivery to mitochondria in living cells. J Control Release 2003. (In press)
44. Smith RA, Porteous CM, Coulter CV, Murphy MP. Selective targeting of an antioxidant to mitochondria. Eur J Biochem 1999; 263(3):709-16.
45. Preston TJ, Abadi A,Wilson L, Singh G. Mitochondrial contributions to cancer cell physiology: potential for drug development. Adv Drug Deliv Rev 2001; 49(1-2):45-61.
46. Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, Natale C, Santacroce R, Di Corcia MG, Lucchese A, Dini L, et al. Cell death: apoptosis versus necrosis (review). Int J Oncol 2002; 21(1):165-70.
47. Malmusi M, Ackerman AB. A critical review of apoptosis in historical perspective. Am J Dermatopathol 2000; 22(3):291-3.
48. Robertson JD, Orrenius S, Zhivotovsky B. Review: nuclear events in apoptosis. J Struct Biol 2000; 129(2-3):346-58.
49. Decaudin D, Marzo II, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy (review). Int J Oncol 1998; 12(1):141-52.
50. Sheard MA. Apoptosis update: to be, or not to be, and how to arrange the latter. Meeting review. Neoplasma 1997; 44(3):202-204.
51. Olasode BJ. Dying by default, the biology of apoptosis: a review. East Afr Med J 1997; 74(2):108-11.
52. Tomei LD, Umansky SR. Apoptosis and the heart: a brief review. Ann N Y Acad Sci 2001; 946:160-8.
53. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 2001; 27(4):257-74.
54. Tinaztepe K, Ozen S, Gucer S, Ozdamar S. Apoptosis in renal disease: a brief review of the literature and report of preliminary findings in childhood lupus nephritis. Turk J Pediatr 2001; 43(2):133-8.
55. Zusman I, Gurevich P, Gurevich E, Ben-Hur H. The immune system, apoptosis and apoptosis-related proteins in human ovarian tumors (a review). Int J Oncol 2001; 18(5):965-72.
56. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin,and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 2002; 82 (4):913-23.
57. Xue L, Borutaite V, Tolkovsky AM. Inhibition of mitochondrial permeability transition and release of cytochrome c by anti-apoptotic nucleoside analogues. Biochem Pharmacol 2002; 64(3):441-9.
58. Kim TS,Jeong DW, Yun BY, Kim IY. Dysfunction of rat liver mitochondria by selenite: induction of mitochondrial permeability transition through thiol-oxidation. Biochem Biophys Res Commun 2002; 294(5):1130-7.
59. Custodio JB, Cardoso CM, Madeira VM, Almeida LM. Mitochondrial permeability transition induced by the anticancer drug etoposide. Toxicol In Vitro 2001; 15 (4-5):265-70.
60. Hail N Jr, Lotan R. Mitochondrial permeability transition is a central coordinating event in N-(4-hydroxyphenyl)retinamide-induced apoptosis. Cancer Epidemiol Biomarkers Prev 2000; 9(12):1293-301.
61. Lemasters JJ, Qian T, Trost LC, Herman B, Cascio WE, Bradham CA, Brenner DA, Nieminen AL. Confocal microscopy of the mitochondrial permeability transition in necrotic and apoptotic cell death. Biochem Soc Symp 1999; 66:205-222.
62. Scorrano L, Petronilli V, Di Lisa F, Bernardi P. Commitment to apoptosis by GD3 ganglioside depends on opening of the mitochondrial permeability transition pore. J Biol Chem 1999; 274(32):22581-5.
63. Lemasters JJ, Qian T, Elmore SP, Trost LC, Nishimura Y, Herman B, Bradham CA, Brenner DA, Nieminen AL. Confocal microscopy of the mitochondrial permeability transition in necrotic cell killing, apoptosis and autophagy. Biofactors 1998; 8(3-4):283-5.
64. Takeyama N, Miki S, Hirakawa A, Tanaka T. Role of the mitochondrial permeability transition and cytochrome C release in hydrogen peroxide-induced apoptosis. Exp Cell Res 2002; 274(1):16-24.
65. Higuchi H, Adachi M, Miura S, Gores GJ, Ishii H. The mitochondrial permeability transition contributes to acute ethanol-induced apoptosis in rat hepatocytes. Hepatology 2001; 34(2):320-8.
66. Liu J,Yoshikawa H, Nakajima Y, Tasaka K. Involvement of mitochondrial permeability transition and caspase-9 activation in dimethyl sulfoxide-induced apoptosis of EL-4 lymphoma cells. Int Immunopharmacol 2001; 1(1):63-74.
67. Feldmann G, Haouzi D, Moreau A, Durand-Schneider AM, Bringuier A, Berson A, Mansouri A, Fau D, Pessayre D. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. Hepatology 2000; 31(3):674-83.
68. Hirpara JL, Seyed MA, Loh KW, Dong H, Kini RM, Pervaiz S. Induction of mitochondrial permeability transition and cytochrome C release in the absence of caspase activation is insufficient for effective apoptosis in human leukemia cells. Blood 2000; 95(5):1773-80.
69. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998; 1366(1-2):177-96.
70. Hirsch T, Susin SA, Marzo I, Marchetti P, Zamzami N, Kroemer G. Mitochondrial permeability transition in apoptosis and necrosis. Cell Biol Toxicol 1998; 14(2):141-5.
71. Hirsch T, Marzo I, Kroemer G. Role of the mitochondrial permeability transition pore in apoptosis. Biosci Rep 1997; 17(1):67-76.
72. Berman SB, Watkins SC, Hastings TG. Quantitative biochemical and ultrastructural comparison of mitochondrial permeability transition in isolated brain and liver mitochondria: evidence for reduced sensitivity of brain mitochondria. Exp Neurol 2000; 164(2):415-25.
73. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341(Pt 2):233-49.
74. Fontaine E, Bernardi P. Progress on the mitochondrial permeability transition pore: regulation by complex I and ubiquinone analogs. J Bioenerg Biomembr 1999; 31(4):335-45.
75. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 2002; 84(2-3):153-66.
76. Madesh M, Hajnoczky G. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol 2001; 155(6):1003-15.
77. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001; 2(1):67-71.
78. Beutner G, Ruck A, Riede B, Brdiczka D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim Biophys Acta 1998; 1368(1):7-18.
79. Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays 2000; 22(11):1007-17.
80. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000; 92(13):1042-53.
81. Borecky J, Mala IG, Arruda P. Mitochondrial uncoupling proteins in mammals and plants. Biosci Rep 2001; 21(2):201-12.
82. Crowley V, Vidal-Puig AJ. Mitochondrial uncoupling proteins (UCPs) and obesity. Nutr Metab Cardiovasc Dis 2001; 11(1):70-5.
83. Dalgaard LT, Pedersen O. Uncoupling proteins: functional characteristics and role in the pathogenesis of obesity and Type II diabetes. Diabetologia 2001; 44(8):946-65.
84. Dulloo AG, Samec S. Uncoupling proteins: their roles in adaptive thermogenesis and substrate metabolism reconsidered. Br J Nutr 2001; 86(2):123-39.
85. Hagen T, Vidal-Puig A. Mitochondrial uncoupling proteins in human physiology and disease. Minerva Med 2002; 93(1):41-57.
86. Klingenberg M. Uncoupling proteins - how do they work and how are they regulated. IUBMB Life 2001; 52(3-5):175-9.
87. Klingenberg M, Echtay KS. Uncoupling proteins: the issues from a biochemist point of view. Biochim Biophys Acta 2001; 1504(1):128-43.
88. Kozak LP, Harper ME. Mitochondrial uncoupling proteins in energy expenditure. Annu Rev Nutr 2000; 20:339-63.
89. Porter RK. Mitochondrial proton leak: a role for uncoupling proteins 2 and 3? Biochim Biophys Acta 2001; 1504(1):120-7.
90. Ricquier D, Bouillaud F. Mitochondrial uncoupling proteins: from mitochondria to the regulation of energy balance. J Physiol 2000; 529(Pt 1):3-10.
91. Enerback S, Jacobsson A, Simpson EM, Guerra C, Yamashita H, Harper ME, Kozak LP. Mice lacking mitochondrial uncoupling protein are cold-sensitive but not obese. Nature 1997; 387(6628):90-4.
92. Monemdjou S, Kozak LP, Harper ME. Mitochondrial proton leak in brown adipose tissue mitochondria of Ucp1-deficient mice is GDP insensitive. Am J Physiol 1999; 276(6 Pt 1):E1073-82.
93. Monemdjou S, Hofmann WE, Kozak LP, Harper ME. Increased mitochondrial proton leak in skeletal muscle mitochondria of UCP1-deficient mice. Am J Physiol Endocrinol Metab 2000; 279(4):E941-6.
94. Ueno H, Miyoshi H, Ebisui K, Iwamura H. Comparison of the inhibitory action of natural rotenone and its stereoisomers with various NADH-ubiquinone reductases. Eur J Biochem 1994; 225(1):411-7.
95. Loffer M, Schneider F. Further characterization of the growth inhibitory effect of rotenone on in vitro cultured Ehrlich ascites tumour cells. Mol Cell Biochem 1982; 48(2):77-90.
96. Isenberg JS, Klaunig JE. Role of the mitochondrial membrane permeability transition (MPT) in rotenone-induced apoptosis in liver cells. Toxicol Sci 2000; 53(2):340-51.
97. Fang J, Wang Y, Beattie DS. Isolation and characterization of complex I, rotenone-sensitive NADH: ubiquinone oxidoreductase, from the procyclic forms of Trypanosoma brucei. Eur J Biochem 2001; 268(10):3075-82.
98. Tormo JR, Gonzalez MC, Cortes D, Estornell E. Kinetic characterization of mitochondrial complex I inhibitors using annonaceous acetogenins. Arch Biochem Biophys 1999; 369(1):119-26.
99. Fevrier A, Ferreira ME, Fournet A, Yaluff G, Inchausti A, Rojas de Arias A, Hocquemiller R, Waechter AI. Acetogenins and other compounds from Rollinia emarginata and their antiprotozoal activities. Planta Med 1999; 65(1):47-9.
100. Morin D, Hauet T, Spedding M, Tillement J. Mitochondria as target for antiischemic drugs. Adv Drug Deliv Rev 2001; 49(1-2):151-74.
101. Crompton M, Costi A, Hayat L. Evidence for the presence of a reversible Ca2+-dependent pore activated by oxidative stress in heart mitochondria. Biochem J 1987; 245(3):915-8.
102. Crompton M, Virji S, Doyle V, Johnson N, Ward JM. The mitochondrial permeability transition pore. Biochem Soc Symp 1999; 66:167-79.
103. Woodfield K, Ruck A, Brdiczka D, Halestrap AP. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem J 1998; 336 (Pt 2):287-90.
104. Chen LB. Mitochondrial membrane potential in living cells. Ann Rev Cell Biol 1988; 4:155-181.
105. Indig GL, Anderson GS, Nichols MG, Bartlett JA, Mellon WS, Sieber F. Effect of molecular structure on the performance of triarylmethane dyes as therapeutic agents for photochemical purging of autologous bone marrow grafts from residual tumor cells. J Pharm Sci 2000; 89(1):88-99.
106. Modica-Napolitano JS, Aprille JR. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 2001; 49(1-2):63-70.
107. Morgan J, Oseroff AR. Mitochondria-based photodynamic anti-cancer therapy. Adv Drug Deliv Rev 2001; 49(1-2):71-86.
108. Murphy MP. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol 1997; 15(8):326-30.
109. Muratovska A, Lightowlers RN, Taylor RW, Wilce JA, Murphy MP. Targeting large molecules to mitochondria. Adv Drug Deliv Rev 2001; 49(1-2):189-98.
110. Flermonte G, Palmieri L, Todisco S, Agrimi G, Palmieri F, Walker JE. Identification of the mitochondrial glutamate transporter. Bacterial expression, reconstitution, functional characterization, and tissue distribution of two human isoforms. J Biol Chem 2002; 277(22):19289-94.
111. Dolce V, Flermonte G, Runswick MJ, Palmieri F, Walker JE. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci USA 2001; 98(5):2284-8.
112. Flermonte G, Dolce V, Palmieri L, Ventura M, Runswick MJ, Palmieri F, Walker JE. Identification of the human mitochondrial oxodicarboxylate carrier. Bacterial expression, reconstitution, functional characterization, tissue distribution, and chromosomal location. J Biol Chem 2001; 276(11):8225-30.
113. Palmieri F, Bisaccia F, Capobianco L, Dolce V, Flermonte G, Iacobazzi V, Indiveri C, Palmieri L. Mitochondrial metabolite transporters. Biochim Biophys Acta 1996; 1275(1-2):127-32.
114. Daum G. Lipids of mitochondria. Biochim Biophys Acta 1985; 822(1):1-42.
115. Petit JM, Maftah A, Ratinaud MH, Julien R. 10N-nonyl acridine orange interacts with cardiolipin and allows the quantification of this phospholipid in isolated mitochondria. Eur J Biochem 1992; 209(1):267-73.
116. Maftah A, Petit JM, Julien R. Specific interaction of the new fluorescent dye 10-N-nonyl acridine orange with inner mitochondrial membrane. A lipid-mediated inhibition of oxidative phosphorylation. FEBS Lett 1990; 260(2):236-40.
117. Chang DD, Clayton DA. Mouse RNAase MRP RNA is encoded by a nuclear gene and contains a decamer sequence complementary to a conserved region of mitochondrial RNA substrate. Cell 1989; 56(1):131-9.
118. Murphy MP. Slip and leak in mitochondrial oxidative phosphorylation. Biochim Biophys Acta 1989; 977:123-141.
119. Nicholls DG. The influence of respiration and ATP hydrolysis on the proton-electrochemical gradient across the inner membrane of rat liver mitochondria as determined by ion distribution. Eur J Biochem 1974; 50:305-315.
120. Lemasters JL, Niemen AL, Chacon E, Imberti R, Gores JM, Reece B, Herman B. Use of fluorescent probes to monitor mitochondrial membrane potential in isolated mitochondria, cell suspensions, and cultured cells. In: Lash LH, Jones DP, editors. Mitochondrial Dysfunction. Harcourt Brace: Academic Press, 1993.
121. Liberman EA, Topaly VP, Tsofina LM, Jasaitis AA, Skulachev VP. Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature 1969; 222(198):1076-8.
122. Chen LB, Summerhayes IC, Johnson LV, Walsh ML, Bernal SD, Lampidis TJ. Probing mitochondria in living cells with rhodamine 123. Cold Spring Harb Symp Quant Biol 1982; 46:141-155.
123. Oseroff AR, Ohuoha D, Ara G, McAuliffe D, Foley J, Cincotta L. Intramitochondrial dyes allow selective in vitro photolysis of carcinoma cells. Proc Natl Acad Sci USA 1986; 83(24):9729-33.
124. Morgan J, Whitaker JE, Oseroff AR. GRP78 induction by calcium ionophore potentiates photodynamic therapy using the mitochondrial targeting dye victoria blue BO. Photochem Photobiol 1998; 67(1):155-64.
125. Nass MM. Abnormal DNA patterns in animal mitochondria: ethidium bromide-induced breakdown of closed circular DNA and conditions leading to oligomer accumulation. Proc Natl Acad Sci USA 1970; 67(4):1926-33.
126. Weiss MJ, Wong JR, Ha CS, Bleday R, Salem RR, Steele GD Jr, Chen LB. Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation. Proc Natl Acad Sci USA 1987; 84(15):5444-8.
127. Summerhayes IC, Lampidis TJ, Bernal SD, Nadakavukaren JJ, Nadakavukaren KK, Shepherd EL, Chen LB. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci USA 1982; 79(17):5292-6.
128. Bernal SD, Lampidis TJ, Summerhayes IC, Chen LB. Rhodamine-123 selectively reduces clonal growth of carcinoma cells in vitro. Science 1982; 218(4577):1117-9.
129. Lampidis TJ, Bernal SD, Summerhayes IC, Chen LB. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res 1983; 43(2):716-20.
130. Bernal SD, Lampidis TJ, McIsaac RM, Chen LB. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science 1983; 222(4620):169-72.
131. Lampidis TJ, Hasin Y, Weiss MJ, Chen LB. Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis. Biomed Pharmacother 1985; 39(5):220-6.
132. Nadakavukaren KK, Nadakavukaren JJ, Chen LB. Increased rhodamine 123 uptake by carcinoma cells. Cancer Res 1985; 45(12 Pt 1):6093-9.
133. Kopf-Maier P, Wagner W, Liss E. Induction of cell arrest at G1/S and in G2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro. J Cancer Res Clin Oncol 1983; 106(1):44-52.
134. Kopf-Maier P, Wagner W, Liss E. Cytokinetic behavior of Ehrlich ascites tumor after in vivo treatment with cis-diamminedichloroplatinum(II) and metallocene dichlorides. J Cancer Res Clin Oncol 1981; 102(1):21-30.
135. Bergerat JP, Green C, Drewinko B. Combination chemotherapy in vitro. IV. Response of human colon carcinoma cells to combinations using cis-diamminedichloroplatinum. Cancer Biochem Biophys 1979; 3(4):173-80.
136. Teicher BA, Holden SA, Jacobs JL, Abrams MJ, Jones AG. Intracellular distribution of a platinum-rhodamine 123 complex in cis-platinum sensitive and resistant human squamous carcinoma cell lines. Biochem Pharmacol 1986; 35(19):3365-9.
137. Herman TS, Teicher BA, Chan V, Collins LS, Kaufmann ME, Loh C. Effect of hyperthermia on the action of cis-diamminedichloroplatinum(II), rhodamine 123(2) [tetrachloroplatinum(II)], rhodamine 123, and potassium tetrachloroplatinate in vitro and in vivo. Cancer Res 1988; 48(9):2335-41.
138. Davis S, Weiss MJ, Wong JR, Lampidis TJ, Chen LB. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 1985; 260(25):13844-50.
139. Modica-Napolitano JS, Aprille JR. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res 1987; 47(16):4361-5.
140. Arcadi JA. Rhodamine-123 as effective agent in rat prostate tumor R3327-H. Preliminary report. Urology 1986; 28(6):501-3.
141. Darzynkiewicz Z, Traganos F, Staiano-Coico L, Kapuscinski J, Melamed MR. Interaction of rhodamine 123 with living cells studied by flow cytometry. Cancer Res 1982; 42(3):799-806.
142. Ara G, Kusumoto T, Korbut TT, Cullere-Luengo F, Teicher BA. cis-Diamminedichlo roplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement. Cancer Res 1994; 54(6):1497-502.
143. Murphy MP. Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction. Expert Opin Biol Ther 2001; 1(5):753-64.
144. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82(1):47-95.
145. Monti D, Moretti L, Salvioli S, Straface E, Malorni W, Pellicciari R, Schettini G, Bisaglia M, Pincelli C, Fumelli C, et al. C60 carboxyfullerene exerts a protective activity against oxidative stress-induced apoptosis in human peripheral blood mononuclear cells. Biochem Biophys Res Commun 2000; 277(3):711-7.
146. Corona-Morales AA, Castell A, Escobar A, Drucker-Colin R, Zhang L. Fullerene C60 and ascorbic acid protect cultured chromaffin cells against levodopa toxicity. J Neurosci Res 2003; 71(1):121-6.
147. Bisaglia M, Natalini B, Pellicciari R, Straface E, Malorni W, Monti D, Franceschi C, Schettini G. C3-fullero-tris-methanodicarboxylic acid protects cerebellar granule cells from apoptosis. J Neurochem 2000; 74(3):1197-204.
148. Lin AM, Fang SF, Lin SZ, Chou CK, Luh TY, Ho LT. Local carboxyfullerene protects cortical infarction in rat brain. Neurosci Res 2002; 43(4):317-21.
149. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001; 276(7):4588-96.
150. Coulter CV, Kelso GF, Lin TK, Smith RA, Murphy MP. Mitochondrially targeted antioxidants and thiol reagents. Free Radic Biol Med 2000; 28(10):1547-54.
151. Dessolin J, Schuler M, Quinart A, De Giorgi F, Ghosez L, Ichas F. Selective targeting of synthetic antioxidants to mitochondria: towards a mitochondrial medicine for neurodegenerative diseases? Eur J Pharmacol 2002; 447(2-3):155-61.
152. Burns RJ, Murphy MP. Labeling of mitochondrial proteins in living cells by the thiol probe thiobutyltriphenylphosphonium bromide. Arch Biochem Biophys 1997; 339:33-39.
153. Burns RJ, Smith RAJ, Murphy MP. Synthesis and characterization of thiobutyltriphenylphosphonium bromide, a novel thiol reagent targeted to the mitochondrial matrix. Arch Biochem Biophys 1995; 322:60-68.
154. Lin TK, Hughes G, Muratovska A, Blaikie FH, Brookes PS, Darley-Usmar V, Smith RA, Murphy MP. Specific modification of mitochondrial protein thiols in response to oxidative stress: a proteomics approach. J Biol Chem 2002; 277(19):17048-56.
155. DiMauro S, Bonilla E, Davidson MM, Hirano M, Schon EA. Mitochondria in neuromuscular disorders. Biochim Biophys Acta 1998; 1366:199-210.
156. DiMauro S. Lessons from mitochondrial DNA mutations. Semin Cell Dev Biol 2001; 12(6):397-405.
157. DiMauro S, Andreu AL. Mutations in mtDNA: are we scraping the bottom of the barrel? Brain Pathol 2000; 10(3):431-41.
158. Lightowlers RN, Chinnery PF, Turnbull DM, Howell N. Mammalian mitochondrial genetics: heredity, heteroplasmy and disease. Trends Genet 1997; 13:450-455.
159. Taylor RW, Wardell TM, Smith PM, Muratovska A, Murphy MP, Turnbull DM, Lightowlers RN. An antigenomic strategy for treating heteroplasmic mtDNA disorders. Adv Drug Deliv Rev 2001; 49(1-2):121-5.
160. King MP, Attardi G. Injection of mitochondria into human cells leads to a rapid replacement of the endogenous mitochondrial DNA. Cell 1988; 52:811-819.
161. Chrzanowska-Lightowlers ZM, Lightowlers RN, Turnbull DM. Gene therapy for mitochondrial DNA defects: is it possible? Gene Ther 1995; 2(5):311-6.
162. Taylor RW, Chinnery PF, Turnbull DM, Lightowlers RN. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nat Genet 1997; 15(2):212-5.
163. Muratovska A, Lightowlers RN, Taylor RW, Turnbull DM, Smith RA,Wilce JA, Martin SW, Murphy MP. Targeting peptide nucleic acid (PNA) oligomers to mitochondria within cells by conjugation to lipophilic cations: implications for mitochondrial DNA replication, expression and disease. Nucleic Acids Res 2001; 29(9):1852-63.
164. De Rosa M, Gambacorta A, Gliozi A. Microbiol Rev 1986; 50:70-80.
165. Gambacorta A, Gliozi A, De Rosa M. World J. Microbiol Biotechnol 1995; 11:115-131.
166. Weissig V, Torchilin VP. Cationic single-chain bolaamphiphiles as new materials for application in medicine and biotechnology. Materials Research Society Meeting, 1999 November 29-December 3; Boston, MA (USA).
167. Weissig V, Mogel HJ, Wahab M, Lasch J. Computer simulations of DQAsomes. Proc Int Symp Control Release Bioact Mater, 1998; Las Vegas, Nevada. Controlled Release Society, 312.
168. Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes J. DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm Res 1998; 15(2):334-7.
169. Weissig V, Lizano C, Ganellin CR, Torchilin VP. DNA binding cationic bolasomes with delocalized charge center: A structure-activity relationship study. STP Pharma Sci 2001; 11:91-96.
170. Weissig V, Cheng SM, D'Souza GG, Torchilin VP, Schubert R, Kimpfler A. Towards mitochondria-specific delivery of apoptosis-inducing agents: DQAsomal incorporated paclitaxel. 2003; Glasgow, Scotland. Control Release Soc.
171. Ledley FD. Pharmaceutical approach to somatic gene therapy. Pharm Res 1996; 13(11):1595-614.
172. Duguid JG, Durlund RH. DNA packaging: non-viral systems. In: Roland A, editor. Advanced Gene Delivery. Amsterdam: Harwood Academic Publishers, 1999.
173. Weissig V, Torchilin VP. Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy. Curr Pharm Biotechnol 2000; 1(4):325-46.
174. Lasch J, Meye A, Taubert H, Koelsch R, Mansaard J, Weissig V. Dequalinium vesicles form stable complexes with plasmid DNA which are protected from DNase attack. Biol Chem 1999; 380(6):647-52.
175. Weissig V, Lizano C, Torchilin VP. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv 2000; 7(1):1-5.
176. Weissig V, D'Souza GG, Torchilin VP. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J Control Release 2001; 75(3):401-8.
177. Weissig V, Seibel P, Seibel M, Torchilin VP. Binding and release of DNA-peptide conjugates by cationic mitochondriotropic vesicles (DQAsomes). 2001; San Diego, CA. Control Release Soc.
178. D'Souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V. DQAsome-mediated plasmid DNA delivery to mitochondria in living cells. J Control Release 2003. (In press.)
179. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998; 55(1):5-30.
180. Seligson AL, Terry RC, Bressi JC, Douglass JG 3rd, Sovak M. A new prodrug of paclitaxel: synthesis of Protaxel. Anticancer Drugs 2001; 12(4):305-13.
181. Andre N, Carre M, Brasseur G, Pourroy B, Kovacic H, Briand C, Braguer D. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett 2002; 532(1-2):256-60.
182. Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998; 58(19):4453-60.
183. Waterhouse NJ, Ricci JE, Green DR. And all of a sudden it's over: mitochondrial outer-membrane permeabilization in apoptosis. Biochimie 2002; 84(2-3):113-21.
184. Discher ED, Eisenberg A. Polymer vesicles. Science 2002; 297:967-73.
185. Hockenbery DM. A mitochondrial Achilles' heel in cancer? Cancer Cell 2002; 2:1-2.
186. Manetta A, Gamboa G, Nasseri A, Podnos YD, Emma D, Dorion G, Rawlings
187. Rideout DC, Calogeropoulou T, Jaworski JS, Dagnino R Jr, McCarthy MR. Phosphonium salts exhibiting selective anti-carcinoma activity in vitro. Anticancer Drug Res 1989; 4(4):265-80.
188. Rideout D, Bustamante A, Patel J. Mechanism of inhibition of FaDu hypopharyngeal carcinoma cell growth by tetraphenylphosphonium chloride. Int J Cancer 1994; 57(2):247-53.
189. Roman SK,Jeitner TM, Hancock R, Cooper WA, Rideout DC, Delikatny EJ. Induction of magnetic resonance-visible lipid in a transformed human breast cell line by tetraphenylphosphonium chloride. Int J Cancer 1997; 73(4):570-9.
190. Delikatny EJ, Roman SK, Hancock R, Jeitner TM, Lander CM, Rideout DC, Mountford CE. Tetraphenylphosphonium chloride induced MR-visible lipid accumulation in a malignant human breast cell line. Int J Cancer 1996; 67(1):72-9.
191. Cooper WA, Bartier WA, Rideout DC, Delikatny EJ. 1H NMR visible lipids are induced by phosphonium salts and 5-fluorouracil in human breast cancer cells. Magn Reson Med 2001; 45(6):1001-10.
192. Delikatny EJ, Cooper WA, Brammah S, Sathasivam N, Rideout DC. Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res 2002; 62(5):1394-400.
193. Manetta A, Gamboa-Vujicic G, Emma D, Patel J, Rideout D. Phosphonium salts exhibit potent anticarcinoma activity in vitro against multidrug resistant ovarian cancer cell lines. Proc Am Assoc Cancer Res, 1993 May 19-22.
194. Manetta A, Gamboa-Vujicic G, Carpenter PM, Rawlings L, Emma D, Mauch S, Patel D, Rideout D. Antitumor activity of APPCL, an antimitochondrial phosphonium salt, against a multidrug resistant human ovarian xenograft model. Proc Am Assoc Cancer Res, 1994.
195. Manetta A, Gamboa-Vujicic G, Nasseri A, Bolton D, Emma D, Bustamante A, Patel J, Rideout D. APPCL, an antimitochondrial phosphonium salt, inhibits the growth of multiple drug-resistant ovarian carcinoma cells. Proc Am Assoc Cancer Res, 1994.
196. Baptista MS, Indig GL. Effect of BSA binding on photophysical and photochemical properties of triarylmethane dyes. J Phys Chem 1998; 102:4778-4688.
197. Kandela IK, Bartlett JA, Indig GL. Effect of molecular structure on the selective phototoxicity of triarylmethane dyes towards tumor cells. Photochem Photobiol Sci 2002; 1:309-314.
198. Lewis LM, Indig GL. Effect of dye aggregation on triarylmethane-mediated photo-induced damage of hexokinase and DNA. J Photochem Photobiol B 2002; 67(3):139-48.
199. Bartlett JA, Indig GL. Effect of self-association and protein binding on the photo-chemical reactivity of triarylmethanes. Implications of noncovalent interactions on the competition between photosensitization mechanisms type I and type II. Photochem Photobiol 1999; 70(4):490-8.
200. Kowaltowski AJ, Turin J, Indig GL, Vercesi AE. Mitochondrial effects of triarylmethane dyes. J Bioenerg Biomembr 1999; 31(6):581-90.
201. Modica-Napolitano JS, Joyal JL, Ara G, Oseroff AR, Aprille JR. Mitochondrial toxicity of cationic photosensitizers for photochemotherapy. Cancer Res 1990; 50(24):7876-81.
202. Gadelha FR, Moreno SN, De Souza W, Cruz FS, Docampo R. The mitochondrion of Trypanosoma cruzi is a target of crystal violet toxicity. Mol Biochem Parasitol 1989; 34(2):117-26.
203. Fiedorowicz M, Pituch-Noworolska A, Zembala M. The photodynamic effect of Victoria blue BO on peripheral blood mononuclear and leukemic cells. Photochem Photobiol 1997; 65(5):855-61.
204. Coulter CV, Smith RAJ, Murphy MP. Synthesis, characterization, and biological properties of a fullerene triphenylphosphonium salt. Fullerene Sci Technol 2001; 9:339-350.
205. Chen Y, Graham A, Potter W, Morgan J, Vaughan L, Bellnier DA, Henderson BW, Oseroff A, Dougherty TJ, Pandey RK. Bacteriopurpurinimides: highly stable and potent photosensitizers for photodynamic therapy. J Med Chem 2002; 45(2):255-8.
206. Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Cramer J, Collins W, et al. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin Cancer Res 2000; 6(1):42-9.
207. Nocentini S, Moreno G, Petit PX, Guggiari M, Salet C, Demerseman P, Dodin G. Induction of mitochondrial dysfunction and apoptosis in HeLa cells by bis-pyridinium oximes, a newly synthesized family of lipophilic biscations. Biochem Pharmacol 1997; 53(10):1543-52.
208. Moreno G, Nocentini S, Guggiari M, Salet C. Effects of the lipophilic biscation, bispyridinium oxime BP12, on bioenergetics and induction of permeability transition in isolated mitochondria. Biochem Pharmacol 2000; 59(3):261-6.
209. Adams DM, Ji W, Barth RF, Tjarks W. Comparative in vitro evaluation of dequalinium B, a new boron carrier for neutron capture therapy (NCT). Anticancer Res 2000; 20(5B):3395-402.
210. Kuin A, Aalders M, van der Valk MA, Frey A, Schmidt HH, Smets LA. Renal toxicity of the neuron-blocking and mitochondriotropic agent m-iodobenzylguanidine. Cancer Chemother Pharmacol 1998; 42:37-45.
211. Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, Leder P. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2002; 2(1):29-42.
212. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13(1):238-52.
213. Bangham AD, Standish MM, Weissmann G. The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. J Mol Biol 1965; 13(1):253-9.
214. Bangham AD, Standish MM, Miller N. Cation permeability of phospholipid model membranes: effect of narcotics. Nature 1965; 208(17):1295-7.
215. Gregoriadis G, Ryman BE. Lysosomal localization of-fructofuranosidase-containing liposomes injected into rats. Biochem J 1972;129(1):123-33.
216. Gregoriadis G, Ryman BE. Lysosomal localization of enzyme-containing liposomes injected into rats. Biochem J 1972; 128(4):142P-143P.
217. Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med 1976; 295 (14):765-70.
218. Gregoriadis G. Liposomes in therapeutic and preventive medicine: the development of the drug-carrier concept. Ann NY Acad Sci 1978; 308:343-70.
219. Torchilin VP, Weissig V, editors. Liposomes: A practical approach. Oxford: Oxford University Press, 2003.
220. Banerjee R. Liposomes: applications in medicine. J Biomater Appl 2001; 16(1):3-21.
221. Kreuter J, editor. Colloidal Drug Delivery Systems. New York: Marcel Dekker, 1994; 353.
222. Lasic DD, Martin FJ, editors. Stealth Liposomes. Boca Raton, FL: CRC Press, 1995; 289.
223. Lasic DD, editor. Liposomes in Gene Delivery. Boca Raton, FL: CRC Press, 1997; 295.
224. Lasic DD, Papahadjopoulos D, editors. Medical Applications of Liposomes. Amsterdam-New York: Elsevier, 1998; 779.
225. Woodle MC, Storm G, editors. Long Circulating Liposomes: Old Drugs, New Tnerapeutics. Austin: Landes Bioscience, 1998; 301.
226. Janoff AS, NetLibrary Inc., editors. Liposomes Rational Design. New York: Marcel Dekker, 1999; 451.
227. Schreier H, editor. Drug Targeting Technology: Physical, Chemical, Biological Methods. New York: Marcel Dekker, 2001; 294.
228. Gregoriadis G, editor. Liposome Technology. Boca Raton, FL: CRC Press, 1993; 3.
229. Basu SC, Basu M, editors. Liposome Methods and Protocols. Totowa, NJ: Humana Press, 2002; 249.
230. Lasic DD, Martin FJ, editors. Stealth Liposomes. Boca Raton, FL: CRC Press, 1995; 289.
231. Philippot JR, Schuber F, editors. Liposomes as Tools in Basic Research and Industry. Boca Raton, FL: CRC Press, 1995; 277
232. Zhai D, Huang X, Han X, Yang F. Characterization of tBid-induced cytochrome c release from mitochondria and liposomes. FEBS Lett 2000; 472(2-3):293-6.
233. Antonsson B, Montessuit S, Lauper S, Eskes R, Martinou JC. Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J 2000; 345(Pt 2):271-8.
234. Brookes PS, Hulbert AJ, Brand MD. The proton permeability of liposomes made from mitochondrial inner membrane phospholipids: no effect of fatty acid composition. Biochim Biophys Acta 1997; 1330(2):157-64.
235. Cocco T, Di Paola M, Minuto M, Carlino V, Papa S, Lorusso M. Steady-state proton translocation in bovine heart mitochondrial bc1 complex reconstituted into liposomes. J Bioenerg Biomembr 1997; 29(1):81-7.
236. Vazquez-Contreras E, de Gomez-Puyou MT, Dreyfus G. A column centrifugation method for the reconstitution in liposomes of the mitochondrial FOF1 ATP synthase/ ATPase. Protein Expr Purif 1996; 7(2):55-9.
237. Vazquez-Contreras E, Vazquez-Laslop N, Dreyfus G. The native F0F1-inhibitor protein complex from beef heart mitochondria and its reconstitution in liposomes. J Bioenerg Biomembr 1995; 27(1):109-16.
238. Deisinger B, Nawroth T, Zwicker K, Matuschka S, John G, Zimmer G, Freisleben HJ. Purification of ATP synthase from beefheart mitochondria (FOF1) and co-reconstitution with monomeric bacteriorhodopsin into liposomes capable of light-driven ATP synthesis. Eur J Biochem 1993; 218(2):377-83.
239. Wunder UR, Colombini M. Patch clamping VDAC in liposomes containing whole mitochondrial membranes. J Membr Biol 1991; 123(1):83-91.
240. Cooper CE, Nicholls P. Structure and vectorial properties of proteoliposomes containing cytochrome oxidase in the submitochondrial orientation. Biochemistry 1990; 29(16):3865-71.
241. Kakar SS, Mahdi F, Li XQ, Garlid KD. Reconstitution of the mitochondrial non-selective Na+/H+ (K+/H+) antiporter into proteoliposomes. J Biol Chem 1989; 264(10):5846-51.
242. Hommes FA, Eller AG, Evans BA, Carter AL. Reconstitution of ornithine transport in liposomes with Lubrol extracts of mitochondria. FEBS Lett 1984; 170(1):131-4.
243. Cheneval D, Muller M, Carafoli E. The mitochondrial phosphate carrier reconstituted in liposomes is inhibited by doxorubicin. FEBS Lett 1983; 159(1-2):123-6.
244. Saint-Macary M, Foucher B. Reconstitution of the dicarboxylate exchange activity by incorporation into liposomes of a Triton-extract of mitochondrial rat-liver inner membranes. Biochem Biophys Res Commun 1983; 113(1):205-11.
245. Eytan GD, Matheson MJ, Racker E. Incorporation of mitochondrial membrane proteins into liposomes containing acidic phospholipids. J Biol Chem 1976; 251(21):6831-7.
246. Jasaitis AA, Nemecek IB, Severina, II, Skulachev VP, Smirnova SM. Membrane potential generation by two reconstituted mitochondrial systems: liposomes inlayed with cytochrome oxidase or with ATPase. Biochim Biophys Acta 1972; 275(3):485-90.
247. Jung K, Kunze D, Schulze G, Egger E. Phosphatidylcholine transfer between liposomes and mitochondria. Testing system for the study of specific phospholipid exchange. Acta Biol Med Ger 1975; 34(2):241-6.
248. Butler MM, Tnompson W. Transfer of phosphatidylserine from liposomes or microsomes to mitochondria. Stimulation by a cell supernatant factor. Biochim Biophys Acta 1975; 388(1):52-7.
249. Schneider H, Lemasters JJ, Hochli M, Hackenbrock CR. Fusion of liposomes with mitochondrial inner membranes. Proc Natl Acad Sci USA 1980; 77(1):442-6.
250. Ricchelli F, Gobbo S, Jori G, Moreno G, Vinzens F, Salet C. Photosensitization of mitochondria by liposome-bound porphyrins. Photochem Photobiol 1993; 58(1):53-8.
251. Lancrajan I, Diehl HA, Socaciu C, Engelke M, Zorn-Kruppa M. Carotenoid incorporation into natural membranes from artificial carriers: liposomes and beta-cyclodextrins. Chem Phys Lipids 2001; 112(1):1-10.
252. Cudd A, Labbe H, Gervais M, Nicolau C. Liposomes injected intravenously into mice associate with liver mitochondria. Biochim Biophys Acta 1984; 774(2):169-80.
253. Cudd A, Nicolau C. Intracellular fate of liposome-encapsulated DNA in mouse liver. Analysis using electron microscope autoradiography and subcellular fractionation. Biochim Biophys Acta 1985; 845(3):477-91.
254. Cudd A, Nicolau C. Interaction of intravenously injected liposomes with mouse liver mitochondria. A fluorescence and electron microscopy study. Biochim Biophys Acta 1986; 860(2):201-14.
255. Suntres ZE, Hepworth SR, Shek PN. Pulmonary uptake of liposome-associated alpha-tocopherol following intratracheal instillation in rats. J Pharm Pharmacol 1993; 45(6):514-20.
256. Shek PN, Suntres ZE, Brooks JI. Liposomes in pulmonary applications: physicochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target 1994; 2(5):431-42.
257. Rodal GH, Rodal SK, Moan J, Berg K. Liposome-bound Zn (II)-phthalocyanine. Mechanisms for cellular uptake and photosensitization. J Photochem Photobiol B 1998; 45(2-3):150-9.
258. Leskova GF, Udovichenko VI. Use of phosphatidylcholine liposomes for correction of phospholipid composition of mitochondria from medulla oblongata and frontal lobe during hemorrhagic shock in cats. Biull Eksp Biol Med 1997; 123(4):374-7.
259. Mowri H, Nakagawa Y, Inoue K, Nojima S. Enhancement of the transfer of alpha-tocopherol between liposomes and mitochondria by rat-liver protein(s). Eur J Biochem 1981; 117(3):537-42.
260. Mowri H, Nojima S, Inoue K. Lack of protein-mediated alpha-tocopherol transfer between membranes in the cytoplasm of ascites hepatomas. Lipids 1988; 23(5):459-64.
261. Inoki Y, Hakamata Y, Hamamoto T, Kinouchi T, Yamazaki S, Kagawa Y, Endo H. Proteoliposomes colocalized with endogenous mitochondria in mouse fertilized egg. Biochem Biophys Res Commun 2000; 278(1):183-91.
262. Ledley FD. Non-viral gene therapy. Curr Opin Biotechnol 1994; 5(6):626-36.
263. Kim CK, Haider KH, Lim SJ, Gene medicine: a new field of molecular medicine. Arch Pharm Res 2001; 24(1):1-15.
264. Schatzlein AG. Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs 2001; 12(4):275-304.
265. Godbey WT, Mikos AG. Recent progress in gene delivery using non-viral transfer complexes. J Control Release 2001; 72(1-3):115-25.
266. Clark PR, Hersh EM. Cationic lipid-mediated gene transfer: current concepts. Curr Opin Mol Ther 1999; 1(2):158-76.
267. Weissig V, Torchilin VP. Letter to the Editor. J Liposome Res 1999; 10:93-95.
268. Takano S, Aramaki Y, Tsuchiya S. Induction of apoptosis in macrophages by cationic liposomes. Abstr Millennial World Congr Pharmaceut Sci 2000:74.
269. Aramaki Y, Takano S, Tsuchiya S. Induction of apoptosis in macrophages by cationic liposomes. FEBS Lett 1999; 460(3):472-6.
270. Aramaki Y, Takano S, Arima H, Tsuchiya S. Induction of apoptosis in WEHI 231 cells by cationic liposomes. Pharm Res 2000; 17(5):515-20.
271. Aramaki Y, Takano S, Tsuchiya S. Cationic liposomes induce macrophage apoptosis through mitochondrial pathway. Arch Biochem Biophys 2001; 392(2):245-50.
272. Rao M, Alving CR. Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. Adv Drug Deliv Rev 2000; 41(2):171-88.
273. Xu Y, Szoka FC Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 1996; 35(18):5616-23.
274. Cavadini P, Gakh O, Isaya G. Protein import and processing reconstituted with isolated rat liver mitochondria and recombinant mitochondrial processing peptidase. Methods 2002; 26(4):298-306.
275. Endo T, Kohda D. Functions of outer membrane receptors in mitochondrial protein import. Biochim Biophys Acta 2002; 1592(1):3-14.
276. Gordon DM, Dancis A, Pain D. Mechanisms of mitochondrial protein import. Essays Biochem 2000; 36:61-73.
277. Hood DA, Adhihetty PJ, Colavecchia M, Gordon JW, Irrcher I, Joseph AM, Lowe ST, Rungi AA. Mitochondrial biogenesis and the role of the protein import pathway. Med Sci Sports Exerc 2003; 35(1):86-94.
278. Jensen RE, Johnson AE. Opening the door to mitochondrial protein import. Nat Struct Biol 2001; 8(12):1008-10.
279. Moro F, Okamoto K, Donzeau M, Neupert W, Brunner M. Mitochondrial protein import: molecular basis of the ATP-dependent interaction of MtHsp70 with Tim44. J Biol Chem 2002; 277(9):6874-80.
280. Pfanner N, Wiedemann N. Mitochondrial protein import: two membranes, three translocases. Curr Opin Cell Biol 2002; 14(4):400-11.
281. Pfanner N, Truscott KN. Powering mitochondrial protein import. Nat Struct Biol 2002; 9(4):234-6.
282. Koehler CM, Jarosch E, Tokatlidis K, Schmid K, Schweyen RJ, Schatz G. Import of mitochondrial carriers mediated by essential proteins of the intermembrane space. Science 1998; 279(5349):369-73.
283. Koehler CM, Merchant S, Schatz G. How membrane proteins travel across the mitochondrial intermembrane space. Trends Biochem Sci 1999; 24(11):428-32.
284. Koehler CM. Protein translocation pathways of the mitochondrion. FEBS Lett 2000; 476(1-2):27-31.
285. Murphy MP, Leuenberger D, Curran SP, Oppliger W, Koehler CM. The essential function of the small Tim proteins in the TIM22 import pathway does not depend on formation of the soluble 70-kilodalton complex. Mol Cell Biol 2001; 21(18):6132-8.
286. Lithgow T. Targeting of proteins to mitochondria. FEBS Lett 2000; 476(1-2):22-6.
287. Hammen PK, Waltner M, Hahnemann B, Heard TS, Weiner H. The role of positive charges and structural segments in the presequence of rat liver aldehyde dehydrogenase in import into mitochondria. J Biol Chem 1996; 271(35):21041-8.
288. Hammen PK, Gorenstein DG, Weiner H. Amphiphilicity determines binding properties of three mitochondrial presequences to lipid surfaces. Biochemistry 1996; 35(12):3772-81.
289. Hammen PK, Weiner H. Mitochondrial leader sequences: structural similarities and sequence differences. J Exp Zool 1998; 282(1-2):280-3.
290. Vestweber D, Schatz G. DNA-protein conjugates can enter mitochondria via the protein import pathway. Nature 1989; 338(6211):170-2.
291. Seibel P, Trappe J, Villani G, Klopstock T, Papa S, Reichmann H. Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases. Nucleic Acids Res 1995; 23(1):10-7.
292. Seibel M, Bachmann C, Schmiedel J, Wilken N, Wilde F, Reichmann H, Isaya G, Seibel P. Processing of artificial peptide-DNA conjugates by the mitochondrial intermediate peptidase (MIP). Biol Chem 1999; 380:961-967.
293. Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 1989; 337(6205):387-8.
294. Felgner PL, GadekTR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84(21):7413-7.
295. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179(1):280-5.
296. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular Biology of the Cell. New York-London: Garland Publishing, 1994.